Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Cancer Discovery|2020Cited by 239
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Adi Diab, Mario Sznol et al.|Cancer Discovery|2019Cited by 233
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.Chantale Bernatchez, Adi Diab, Cara Haymaker et al.|Journal of Clinical Oncology|2017Cited by 23
A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.Adi Diab, Mario Sznol, Nizar M. Tannir et al.|Journal of Clinical Oncology|2017Cited by 14
P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor MalignanciesV. Papadimitrakopoulou, Adi Diab, Nizar M. Tannir et al.|Journal of Thoracic Oncology|2017Cited by 5